CRMD's DefenCath, the only FDA-approved antimicrobial catheter lock, saw higher outpatient dialysis use in the fourth quarter ...

The Pitt season premiere, "7:00 a.m.," ignores clichés in favor of a gritty, realistic, and uncompromising take on the ...

CorMedix Therapeutics is a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases.

Q4 2025 Unaudited Net Revenue of Approximately $127 million ‒‒ FY 2025 Unaudited Pro Forma Net Revenue of Approximately $400 million ‒‒ Expects ...

A new Indian study warns that the drug-resistant fungus Candida auris is spreading worldwide and becoming deadlier. Led by researchers from Vallabhbhai Patel Chest Institute with support from the ...

CorMedix Therapeutics (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening ...

Up to 189 health conditions could potentially affect your ability to drive, with seven specific conditions that must be ...

The article " Why CorMedix Could be the Biopharma Name to Watch Early in 2026 " first appeared on MarketBeat.

There are no established treatment options for patients with meningioma recurring after surgery and radiotherapy.

The outlook includes $150 million to $170 million from DefenCath, with results weighted toward the first half of the year.

As many as 189 health conditions could potentially affect your legal ability to drive. Both physical and mental health ...

Drivers could face up to £1,000 fines and potential prosecution if they fail to report notifiable medical conditions or ...